Deep Genomics uses artificial intelligence to transform drug discovery by decoding the intricacies of RNA biology, aiming to identify novel drug targets and therapeutic mechanisms that traditional methods often overlook. Founded in 2015, the company integrates expertise across multiple disciplines, including machine learning, bioinformatics, and drug development, with teams based in Toronto and Cambridge, MA. At the core of Deep Genomics' mission is the development of RNA-targeted therapies, particularly focusing on steric-blocking oligonucleotides for genetic disorders. By leveraging advanced technologies, they seek to revolutionize how new medicines are created and brought to market, while fostering an inclusive working environment that encourages collaboration and innovation among its multidisciplinary staff.